SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE
Brequinar sodium
CAS: 96201-88-6
Molecular Formula: C23H14F2NNaO2
SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE - Names and Identifiers
| Name | Brequinar sodium |
| Synonyms | Dup-785 NSC-368390 Bipenquinate Brequinar sodium 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE 6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium 2-(2'-Fluoro-1,1'-biphenyl-4-yl)-3-methyl-6-fluoroquinoline-4-carboxylic acid sodium salt |
| CAS | 96201-88-6 |
| EINECS | 604-604-1 |
SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE - Physico-chemical Properties
| Molecular Formula | C23H14F2NNaO2 |
| Molar Mass | 397.35 |
| Melting Point | >360° |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Water (up to 15 mg/ml with warming) |
| Appearance | solid |
| Color | Off-white or white |
| Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. |
| Use | Brequinar Sodium is the sodium salt form of Brequinar. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. |
SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE - Reference
| Reference Show more | Note: part of our products can only provide part of the information, our company does not guarantee the authority of the information provided, only for the customer reference Exchange research. configuration solution concentration reference: 1mg5mg10mg1mm2.517ml12.583 ml25.167 ml5mm0.503 ml2.517ml5.033 ml10mm0.252 ml1.258 ml2.517mm50ml0.252 ml0.503 ml storage condition: -20 ℃ solubility: soluble in DMSO 5: Xu X, Gong H, Blinder L, Shen J, Williams JW, Chong. Control of lymphoma and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action. J Pharmacol Exp Ther. 1997 Nov;283(2):869-75. PubMed PMID: 9353408. 4: Joshi AS, King SY, Zajac BA, Makowka L, Sher LS, Kahan BD, Menkis AH, Stiller CR, Schaefle B Kornhauser DM. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. J Clin Pharmacol. 1997 Dec;37(12):1121-8. PubMed PMID: 9506007. 3: Xu X, Williams JW, Shen J, Gong H, Yin DP, Blinder L, Elder RT, Sankary H Finnegan A, Chong AS. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium. J Immunol. 1998 Jan 15;160(2):846-53. PubMed PMID: 9551920. 2: Chastanet S, Cursio R, Gugenheim J, Baldini E, Chevallier A, Damais A, Charpentier B Mouiel J. Brequinar sodium and liver hemoperfusion in xenotransplantation. Transplant Proc. 1998 Aug;30(5):2244-5. PubMed PMID: 9723457. |
![SODIUM 6-FLUORO-2-(2-FLUORO-[1,1-BIPHENYL]-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLATE](http://res.chembk.com/assets/str/2d/9/96/96201-88-6.png)
Supplier List
View History